Volume 2, Issue 4
Evaluation of the Effect of Angiotensin-Converting Enzyme Inhibitors and the Angiotensin II Receptor Blockers on the Dynamics of Mitogenic Growth Factors, Apoptosis Inducers and Pulmonary Artery Systolic Pressure in Patients with Chronic Pulmonary Heart Disease
Author: Vitaliy Seredyuk*
Department of Internal Medicine №2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
Abstract: The dynamics of mitogenic growth factors was investigated, including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and apoptosis inducer Fas-Ligand (FasL), and the level of pulmonary artery systolic pressure (PASP) under the influence of angiotensin-converting enzyme (ACE) enalapril, and the angiotensin II receptor blocker (ARB) candesartan and their combined use in patients with chronic pulmonary heart disease (CPHD). The study involved 282 patients with CPHD, including 55 (19.5%) with compensated and 227 (80.5%) with decompensated CPHD and chronic heart failure (CHF) NYHA Class II-IV. It was found that ACE inhibitor enalapril and the angiotensin II receptor blocker candesartan reduce levels of mitogenic growth factors bFGF, VEGF, apoptosis inducer Fas-Ligand, and PASP in patients with CPHD. Clinical efficacy of long-term (over 6 months) combined use of ACE inhibitor enalapril and the angiotensin II receptor blocker candesartan on the background of a basic therapy in patients with decompensated CPHD and CHF NYHA Class III - IV judging by the dynamics of bFGF, VEGF, FasL , and PASP levels is more pronounced, than during the same treatment but without the angiotensin II receptor blocker.
Download Full Article: Click Here
Related Graphics:
Support Us
If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.
